Rhinomed Limited
RHNMF · OTC
6/30/2023 | 6/30/2022 | 6/30/2021 | 6/30/2020 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.02 | 0.14 | 0.20 | 0.53 |
| FCF Yield | -39.27% | -2.87% | -0.12% | -52.27% |
| EV / EBITDA | -2.67 | -6.37 | -4.69 | -0.57 |
| Quality | ||||
| ROIC | 2,593.78% | -110.50% | -167.07% | -70.17% |
| Gross Margin | -2.55% | 68.16% | 70.67% | 59.32% |
| Cash Conversion Ratio | 0.66 | 1.09 | 0.62 | 0.79 |
| Growth | ||||
| Revenue 3-Year CAGR | 24.26% | 36.69% | 5.83% | 18.01% |
| Free Cash Flow Growth | -729.57% | -1,686.40% | 99.15% | -2,391.93% |
| Safety | ||||
| Net Debt / EBITDA | -0.64 | 0.36 | 0.23 | 1.07 |
| Interest Coverage | -30.08 | -136.18 | -216.70 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 12.17 | 2.33 | 7.27 | 2.68 |
| Cash Conversion Cycle | 21.45 | 12.90 | -72.67 | 92.48 |